2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: Interrelated approaches in drug discovery

Journal of Medicinal Chemistry

Volumn 45, Issue 26, 2002, Pages 5609-5616

  Patchett, Arthur A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPERLICIN; CAPTOPRIL; CARBOXYPEPTIDASE A; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLESTEROL; COMPACTIN; DIPEPTIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GROWTH HORMONE SECRETAGOGUE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; LISINOPRIL; MEVALONIC ACID; MEVINOLIN; NATURAL PRODUCT; PENTAPEPTIDE; PYROGLUTAMYLLYSYLTRYPTOPHYLALANYLPROLINE; SOMATOSTATIN 14; TEPROTIDE; TRIPARANOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHEMICAL REACTION; DRUG ACTIVITY; DRUG ISOLATION; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; NONHUMAN; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; AWARDS AND PRIZES; BENZODIAZEPINONES; BIOLOGICAL PRODUCTS; CHEMISTRY, ORGANIC; DRUG DESIGN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; PORTRAITS; UNITED STATES;

EID: 0037137608     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020424z     Document Type: Review

References (74)

1. Alberts, A. W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Rothrock, J.; Lopez, M.; Joshua, H.; Harris, E.; Patchett, A.; Monaghan, R.; Currie, S.; Stapley, E.; Albers-Schonberg, G.; Hensens, O.; Hirshfield, J.; Hoogsteen, K.; Liesch, J.; Springer, J. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol lowering agent. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 3957-3961.
2. Alberts, A. W. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 1988, 62, 10J-15J.
3. Steinberg, D.; Avigan, J.; Feigelson, E. B. Effects of triparanol (MER-29) on cholesterol biosynthesis and blood sterol levels in man. J. Clin. Invest. 1961, 40, 884-893.
4. Kirby, T. J. Cataracts produced by triparanol (MER-29). Trans. Am. Ophthamol. Soc. 1967, 65, 494-543.
5. Endo, A.; Kuroda, M.; Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot. 1976, 1346-1348.
6. Brown, A. G.; Smale, T. C.; King, T. J.; Hasenkamp, R.; Thompson, R. H. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J. Chem. Soc., Perkin Trans. 1 1976, 1165-1170.
7. Endo, A.; Tsujita, Y.; Kuroda, M.; Tanzawa, K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3methylglutaryl coenzyme A reductase. Eur. J. Biochem. 1977, 77, 31-36.
8. Tsujita, Y.; Kuroda, M.; Tanzawa, K.; Kitano, N.; Endo, A. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 1979, 32, 307-313.
9. Yamamoto, A.; Sudo, H.; Endo, A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980, 35, 259-266.
10. Endo, A. The discovery and development of HMG-COA reductase inhibitors. J. Lipid Res. 1992, 33, 1569-1582.
11. Skeggs, H. R.; Wright, L. D.; Cresson, E. L.; MacRae, G. D. E.; Hoffman, C. H.; Wolf, D. E.; Folkers, K. Discovery of a new acetate-replacing factor. J. Bacteriol. 1956, 72, 519-524.
12. Wolf, D. E.; Hoffman, C. H.; Aldrich, P. E.; Skeggs, H. R.; Wright, L. D.; Folkers, K. Determination of structure of β,δ-dihydroxy-β-methylvaleric acid. J. Am. Chem. Soc. 1957, 79, 1486-1487.
13. Hoffman, C. H.; Wagner, A. F.; Wilson, A. N.; Walton, E.; Shunk, C. H.; Wolf, D. E.; Holly, F. W.; Folkers, K. Synthesis of DL-3,5-dihydroxy-3-methylpentanoic acid (mevalonic acid). J. Am. Chem. Soc. 1957, 79, 2316-2318.
14. Endo, A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Antibiot. 1980, 33, 334-336.
15. Chao, Y.; Chen, J. S.; Hunt, V. M.; Kuron, G. W.; Karkas, J. D.; Liou, R.; Alberts, A. W. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Eur. J. Clin. Pharmacol. 1991, 40 (Suppl. 1), S11-S14.
16. (a) MacDonald, J. S.; Gerson, R. J.; Kornbrust, D. J.; Kloss, M. W.; Prahalada, S.; Berry, P. H.; Alberts, A. W.; Bokelman, D. L. Preclinical evaluation of lovastatin. Am. J. Cardiol. 1988, 62, 16J-27J.
17. (b) Tobert, J. A. Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 1988, 62, 28J-34J.
18. (c) Vagelos, P. R. Are prescription drug prices high? Science 1991, 252, 1080-1084.
19. (a) Illingworth, D. R.; Tobert, J. A. HMG-CoA reductase inhibitors. In Drug Discovery and Design; Scolnick, E. M., Ed.; Advances in Protein Chemistry Vol. 56; Academic Press: San Diego, CA, 2001; pp 77-114.
20. (b) Yusuf, S. Two decades of progress in preventing vascular disease. Lancet 2002, 360, 2-3.
21. (c) Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002, 360, 7-22.
22. (d) Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383-1399.
23. (e) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998, 339, 1349-1357.
24. (f) Sacks, F. M.; Pfeffer, M. A.; Moye, L. A.; Rouleau, J. L.; Rutherford, J. D.; Cole, T. G.; Brown, L.; Warnica, J. W.; Arnold, J. M.; Wun, C. C.; Davis, B. R.; Braunwald, E. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin in coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996, 335, 1001-1009.
25. (a) Nakamura, C. E.; Abeles, R. H. Mode of interaction of β-hydroxy-β-methylglutaryl coenzyme A reductase with strong binding inhibitors: Compactin and related compounds. Biochemistry 1985, 24, 1364-1376.
26. (b) Jencks, W. P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 4046-4050.
27. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins. Science 1997, 278, 497-499.
28. Williams, H. W. R.; Eichler, E.; Randall, W. C.; Rooney, C. S.; Cragoe, E. J.; Streeter, K. B.; Schwam, H.; Michelson, S. R.; Patchett, A. A.; Taub, D. Inhibitors of glycolic acid oxidase. 4-Substituted 2,4-dioxobutanoic acid derivatives. J. Med. Chem. 1983, 26, 1196-1200.
29. Schuman, M.; Massey, V. Effect of anions on the catalytic activity of pig liver glycolic acid oxidase. Biochim. Biophys. Acta 1971, 10, 521-537.
30. Ferreira, S. H. History of the development of inhibitors of angiotensin I conversion. Drugs 1985, 30 (Suppl. 1), 1-5.
31. Bakhla, Y. S. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 1968, 220, 919-921.
32. Bakhla, Y. S.; Reynard, A. M.; Vane, J. R. Metabolism of the angiotensins in isolated perfused tissues. Nature 1969, 222, 956.
33. Ng, K. K. F.; Vane, J. R. Some properties of angiotensin converting enzyme in the lung, in vivo. Nature 1970, 225, 1142-1144.
34. Ondetti, M. A.; Williams, N. J.; Sabo, E. F.; Pluscec, J.; Weaver, E. R.; Kocy, O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jaraca. Isolation, elucidation of structure, and synthesis. Biochemistry 1971, 10, 4033-4039.
35. Ferreira, S. H.; Bartlet, D. C.; Greene, L. J. Isolation of bradykinin-potentiating peptides from Bothrops jaraca venom. Biochemistry 1970, 9, 2583-2593.
36. Brunner, H. R.; Laragh, J. H.; Baer, L.; Newton, M. A.; Goodwin, F. T.; Krakoff, L. R.; Bard, R. H.; Buhler, F. R. Essential hypertension: Renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 1972, 286, 441-449.
37. Gavras, H.; Brunner, H. R.; Laragh, J. H.; Sealey, J. E.; Gavras, I.; Vukovich, R. A. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N. Engl. J. Med. 1974, 291, 817-821.
38. Johnson, J. G.; Black, W. D.; Vukovich, R. A.; Hatch, F. E., Jr.; Friedman, B. I.; Blackwell, C. F.; Shenouda, A. N.; Share, L.; Shade, R. E.; Acchiardo, S. R.; Muirhead, E. E. Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme. Clin. Sci. Mol. Med., Suppl. 1975, 2, 53S-56S.
39. Ondetti, M. A.; Rubin, B.; Cushman, D. W. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977, 196, 441-443.
40. Cushman, D. W.; Cheung, H. S.; Sabo, E. F.; Ondetti, M. A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977, 16, 5484-5491.
41. Ondetti, M. A.; Cushman, D. W.; Rubin, B. Captopril. In Chronicles of Drug Discovery; Bindra, J. S., Lednicer, D., Eds.; John Wiley & Sons: New York, 1983; Vol. 2, pp 1-31.
42. Ondetti, M. A. From peptides to peptidases: A chronicle of drug discovery. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 1-16.
43. Cushman, D. W.; Ondetti, M. A. Design of angiotensin converting enzyme inhibitors. Nat. Med. 1999, 5, 1110-1113.
44. Thorsett, E. D.; Harris, E. E.; Peterson, E. R.; Greenlee, W. J.; Patchett, A. A.; Ulm, E. H.; Vassil, T. C. Proc. Natl. Acad. Sci. U.S.A. 1982, 79, 2176-2180.
45. Patchett, A. A.; Harris, E.; Tristram, E.; Wyvratt, M. J.; Wu, M. T.; Taub, D.; Peterson, E. R.; Ikeler, T. J.; ten Broeke, J.; Payne, L. G.; Ondeyka, D. L.; Thorsett, E. D.; Greenlee, W. J.; Lohr, N. S.; Hoffsommer, R. D.; Joshua, H.; Ruyle, W. V.; Rothrock, J. W.; Aster, S. D.; Maycock, A. L.; Robinson, F. M.; Hirschmann, R.; Sweet, C. S.; Ulm, E. H.; Gross, D. M.; Vassil, T. C.; Stone, C. A. A new class of angiotensin-converting enzyme inhibitors. Nature 1980, 288, 280-283.
46. Byers, L. D.; Wolfenden, R. A potent reversible inhibitor of carboxypeptidase A. J. Biol. Chem. 1972, 247, 606-608.
47. Byers, L. D.; Wolfenden, R. Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A. Biochemistry 1973, 12, 2070-2078.
48. Patchett, A. A. The chemistry of enalapril. Br. J. Clin. Pharmacol. 1984, 18, 201S-207S.
49. Patchett, A. A. Enalapril and lisinopril. In Chronicles of Drug Discovery; Lednicer, D., Ed.; American Chemical Society: Washington, DC, 1993; Vol. 3, pp 125-162.
50. Ulm, E. H. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: Absorption, disposition and metabolism in man. Drug Metab. Rev. 1983, 14, 99-110.
51. Friedman, D. I.; Amidon, G. L. Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: Enalapril and fosinopril. Pharm. Res. 1989, 6, 1043-1047.
52. Yee, S.; Amidon, G. L. Oral absorption of angiotensin converting enzyme inhibitors and peptide prodrugs. In Peptide-Based Drug Design. Controlling Transport and Metabolism; Taylor, M. D., Amidon, G. L., Eds.; American Chemical Society: Washington, DC, 1995; pp 135-147.
53. Friedman, D. I.; Amidon, G. L. Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: Lisinopril and SQ29,852. J. Am. Pharm. Sci. 1989, 78, 995-998.
54. Thorsett, E. D.; Harris, E. E.; Aster, S. D.; Peterson, E. R.; Synder, J. P.; Springer, J. P.; Hirshfield, J.; Tristram, E. W.; Patchett, A. A.; Ulm, E. H.; Vassil, T. C. Conformationally restricted inhibitors of angiotensin converting enzyme: Synthesis and computations. J. Med. Chem 1986, 29, 251-260.
55. Wyvratt, M. J.; Patchett, A. A. Recent developments in the design of angiotensin-converting enzyme inhibitors. Med. Res. Rev. 1985, 5, 483-531.
56. Wyvratt, M. J.; Tischler, M. H.; Ikeler, T. J.; Springer, J. P.; Tristram, E. W.; Patchett, A. A. Bicyclic inhibitors of angiotensin converting enzyme. In Peptides: Structure and Function, Proceedings of the 8th American Peptide Symposium; Hruby, V. J., Rich, D. H., Eds.; Pierce Chemical Co.: Rockford, IL, 1983; pp 551-554.
57. Rich, D. H. Peptidase inhibitors. In Comprehensive Medicinal Chemistry; Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: Oxford, 1990; Vol. 2, pp 391-441.
58. Patchett, A. A.; Cordes, E. H. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme. In Advances in Enzymology and Related Areas of Molecular Biology; Meister, A., Ed.; John Wiley & Sons: New York, 1985; Vol. 57, pp 1-84.
59. Chang, R. S. L.; Lotti, V. J.; Monaghan, R. L.; Birnbaum, J.; Stapley, E. O.; Goetz, M. A.; Albers-Schönberg, G.; Patchett, A. A.; Liesch, J. M.; Hensens, O. D.; Springer, J. P. A potent nonpeptide cholecystokinin receptor antagonist with selectivity for peripheral tissues isolated from Aspergillus alliaceus. Science 1985, 230, 177-179.
60. Evans, B. E.; Bock, M. G.; Rittle, K. E.; DiPardo, R. M.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Design of potent orally effective, nonpeptidyl antagonists of the peptide hormone cholecystokinin. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4918-4922.
61. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem. 1989, 32, 13-16.
62. Yu, M. J.; Thrasher, J.; McCowan, J. R.; Mason, N. R.; Mendelsohn, L. G. Quinazolinone cholecstokinin-B receptor ligands. J. Med. Chem. 1991, 34, 1505-1508.
63. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
64. Patchett, A. A.; Nargund, R. P. Privileged structures - An update. Annu. Rep. Med. Chem. 2000, 35, 289-298.
65. Patchett, A. A.; Nargund, R. P.; Tata, J. R.; Chen, M.-H.; Barakat, K. J.; Johnston, D. B. R.; Cheng, K.; Chan, W. W.-S.; Butler, B.; Hickey, G.; Jacks, T.; Schleim, K.; Pong, S.-S.; Chaung, L.-Y. P.; Chen, H. Y.; Frazier, E.; Leung, K. H.; Chiu, S.-H. L.; Smith, R. G. Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7001-7005.
66. Bowers, C. Y.; Momany, F. A.; Reynolds, G. A.; Hong, A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114, 1537-1545.
67. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402, 656-660.
68. Momany, F. A.; Bowers, C. Y. Computer-assisted modeling of xenobiotic growth hormone secretagogues. In Growth Hormone Secretagogues; Bercu, B. B., Walker, R. F., Eds.; Springer-Verlag: New York, 1996; pp 73-83.
69. Feighner, S. D.; Howard, A. D.; Prendergast, K.; Palyha, O. C.; Hreniuk, D. L.; Nargund, R.; Underwood, D.; Tata, J. R.; Dean, D. C.; Tan, C. P.; McKee, K. K.; Woods, J. W.; Patchett, A. A.; Smith, R. G.; Van der Ploeg, L. H. T. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol. Endocrinol. 1998, 12, 137-145.
70. Nargund, R.; Patchett, A. A.; Bach, M. A.; Murphy, M. G.; Smith, R. G. Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential. J. Med. Chem. 1998, 41, 3103-3127.
71. Veber, D. F. Design and discovery in the development of peptide analogs. In Peptides; Smith, J. A., Rivier, J. E., Eds.; ESCOM: Leiden, The Netherlands, 1992; pp 3-14.
72. Yang, L.; Berk, S. C.; Rohrer, S. P.; Mosley, R. T.; Guo, L.; Underwood, D. J.; Arison, B. H.; Birzin, E. T.; Hayes, E. C.; Mitra, S. W.; Parmar, R. M.; Cheng, K.; Wu, T.-J.; Butler, B. S.; Foor, F.; Pasternak, A.; Pan, Y.; Silva, M.; Freidinger, R. M.; Smith, R. G.; Chapman, K.; Schaeffer, J. M.; Patchett, A. A. Synthesis and biological activities of potent peptiomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10836-10841.
73. (a) Van der Ploeg, L. H. T.; Martin, W. J.; Howard, A. D.; Nargund, R. P.; Austin, C. P.; Guan, X.; Drisko, J.; Cashen, D.; Sebhat, I.; Patchett, A. A.; Figueroa, D. J.; DiLella, A. G.; Connolly, B. M.; Weinberg, D. H.; Tan, C. P.; Palyha, O. C.; Pong, S.-S.; MacNeil, T.; Rosenblum, C.; Vongs, A.; Tang, R.; Yu, H.; Sailer, A. W.; Fong, T. M.; Huang, C.; Tota, M. R.; Chang, R. S.; Stearns, R.; Tamvakopoulos, C.; Christ, G.; Drazen, D. L.; Spar, B. D.; Nelson, R. J.; MacIntyre, D. E. A role for the melanocortin 4 receptor in sexual function. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11381-11386.
74. (b) Sebhat, I. K.; Martin, W. J.; Ye, Z.; Barakat, K.; Mosley, R. T.; Bakshi, R.; Palucki, B.; Tamvakopoulos, C.; Weinberg, D. H.; MacNeil, T.; Kalyani, R. M.; Tang, R.; Stearns, R. A.; Miller, R. R.; Strack, A. M.; McGowan, E.; Casheen, D. E.; Drisko, J. E.; Hom, G. J.; Howard, A. D.; MacIntyre, D. E.; Van der Ploeg, L. H. T.; Patchett, A. A.; Nargund, R. P. Design and pharmacology of N-[(3R)-1,2,3,4-etrahydroisoquinolinium-3-ylcarbonyl]- (1R)-1-(4-chlorobenzyl)-[4-cyclohexyl-4- (1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-xoethylamine (1), a potent, selective melanocortin subtype-4 receptor (MC4R) agonist. J. Med. Chem. 2002, 45, 4589-4593.